Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DERMASEAL Safety Study for Diabetic Foot Ulcers
NCT05586542Phase 1Active, not recruiting
- Sponsor
- Vitruvian Medical Devices
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DERMASEAL in diabetic foot ulcer (DFU) (3 arms), sponsored by Vitruvian Medical Devices. Primary endpoint: Adverse events at 16 weeks. Started Oct 2022; status: active, not recruiting.
02
Drugs
DERMASEAL
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05586542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586542.